Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8


Enhanced antitumor activity of gemcitabine by polysaccharide-induced NK cell activation and immune cytotoxicity reduction in vitro/vivo.

Xie X, Zhou Y, Wang X, Guo J, Li J, Fan H, Dou J, Shen B, Zhou C.

Carbohydr Polym. 2017 Oct 1;173:360-371. doi: 10.1016/j.carbpol.2017.06.024. Epub 2017 Jun 10.


HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2.

De Re V, De Zorzi M, Caggiari L, Lauletta G, Tornesello ML, Fognani E, Miorin M, Racanelli V, Quartuccio L, Gragnani L, Russi S, Pavone F, Ghersetti M, Costa EG, Casarin P, Bomben R, Mazzaro C, Basaglia G, Berretta M, Vaccher E, Izzo F, Buonaguro FM, De Vita S, Zignego AL, De Paoli P, Dolcetti R.

Oncotarget. 2016 Jun 21;7(25):37487-37497. doi: 10.18632/oncotarget.9303.


Antitumor and immunomodulatory effects of recombinant fusion protein rMBP-NAP through TLR-2 dependent mechanism in tumor bearing mice.

Wang T, Liu X, Ji Z, Men Y, Du M, Ding C, Wu Y, Liu X, Kang Q.

Int Immunopharmacol. 2015 Dec;29(2):876-883. doi: 10.1016/j.intimp.2015.08.027. Epub 2015 Sep 16.


TLR2 limits development of hepatocellular carcinoma by reducing IL18-mediated immunosuppression.

Li S, Sun R, Chen Y, Wei H, Tian Z.

Cancer Res. 2015 Mar 15;75(6):986-95. doi: 10.1158/0008-5472.CAN-14-2371. Epub 2015 Jan 19.


Extracellular HSPA1A promotes the growth of hepatocarcinoma by augmenting tumor cell proliferation and apoptosis-resistance.

Wu FH, Yuan Y, Li D, Liao SJ, Yan B, Wei JJ, Zhou YH, Zhu JH, Zhang GM, Feng ZH.

Cancer Lett. 2012 Apr 28;317(2):157-64. doi: 10.1016/j.canlet.2011.11.020. Epub 2011 Nov 22.


Activation of Toll-like receptor 3 impairs the dengue virus serotype 2 replication through induction of IFN-β in cultured hepatoma cells.

Liang Z, Wu S, Li Y, He L, Wu M, Jiang L, Feng L, Zhang P, Huang X.

PLoS One. 2011;6(8):e23346. doi: 10.1371/journal.pone.0023346. Epub 2011 Aug 4.


Helicobacter hepaticus--induced liver tumor promotion is associated with increased serum bile acid and a persistent microbial-induced immune response.

García A, Zeng Y, Muthupalani S, Ge Z, Potter A, Mobley MW, Boussahmain C, Feng Y, Wishnok JS, Fox JG.

Cancer Res. 2011 Apr 1;71(7):2529-40. doi: 10.1158/0008-5472.CAN-10-1975. Epub 2011 Feb 18.


Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help.

Garay RP, Viens P, Bauer J, Normier G, Bardou M, Jeannin JF, Chiavaroli C.

Eur J Pharmacol. 2007 Jun 1;563(1-3):1-17. Epub 2007 Feb 17. Review.


Supplemental Content

Loading ...
Support Center